Cancer treatment methods continue to advance with medical research and technological development, covering traditional therapies, emerging technologies, adjunct therapies, and personalized medicine. This guide provides a comprehensive overview of cancer treatment, supported by scientific research, to assist patients and healthcare professionals in formulating optimal treatment strategies.
After completing cancer care, patients enter the recovery period, but this phase is not foolproof. Although care has ended, the risk of cancer recurrence still exists. Therefore, managing and continuously monitoring the recovery period is crucial. The frequency of monitoring will vary depending on the patient’s specific situation, cancer type, and individual health condition. Through regular monitoring, the medical team can detect potential signs of recurrence early and adjust care plans promptly to reduce the risk of recurrence and promote long-term recovery.
In cancer care, adjusting care plans becomes crucial as a patient’s condition changes. With the advancement of modern care testing technologies, the care team can monitor the patient’s health status and response to care in real-time, adjusting the care plan promptly based on the testing data to achieve optimal outcomes. These testing data not only provide specific information regarding tumor progression but also help the care team understand the patient’s immune status, metabolic features, and other key indicators, thus enabling precise and personalized care.
In cancer care, developing a personalized care plan for each patient is crucial, especially during the initial diagnosis phase. This phase is not only the starting point for medical record collection and diagnosis but also a critical moment for determining the direction of future care. Scientific testing methods can help medical teams fully understand a patient’s health status, cancer risks, metabolic characteristics, and more, thereby establishing a personalized care baseline. These tests provide real-time data that serve as an important reference for future care adjustments.
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, with a high mortality rate. Among its complications, liver metastasis is one of the most common sites for distant spread. Once liver metastasis occurs, the prognosis for the patient significantly worsens. Traditional methods for monitoring colorectal cancer metastasis mostly rely on imaging techniques, such as CT or MRI, which, while helpful in visualizing the tumor, are often limited in detecting small metastases or early-stage changes. Therefore, early detection of liver metastasis and continuous monitoring of disease progression are crucial in formulating an optimal care plan for patients.
In the process of cancer care, advanced-stage patients often face challenges such as rapid disease progression and unstable treatment responses. For these patients, the need for dynamic monitoring is particularly urgent. Traditional monitoring methods often rely on imaging tests and biochemical markers, and the results may lag behind the actual changes in the patient’s condition. With the advancement of technology, modern testing techniques, such as RGCC’s Circulating Tumor Cell (CTC) testing, provide patients with more immediate and accurate disease assessments, helping healthcare providers adjust care plans promptly, improve treatment outcomes, and extend patients’ survival.
In modern medicine, drug metabolism is crucial for the success of treatment. However, exposure to heavy metals can significantly impact the drug metabolism process, which in turn affects therapeutic outcomes. Accumulation of heavy metals in the body can interfere with the function of important organs such as the liver and kidneys, which are responsible for drug metabolism and excretion. Excessive heavy metal burden can lead to either too slow or too fast drug metabolism, thus affecting drug efficacy or causing adverse reactions. Therefore, a basic assessment of heavy metal burden is essential for optimizing drug metabolism and ensuring effective treatment.
Lung cancer remains one of the most common cancers worldwide, with a high mortality rate. One of the primary challenges in lung cancer management is its late diagnosis, as early-stage lung cancer often presents with no obvious symptoms. As a result, many patients are diagnosed at an advanced stage, limiting their treatment options and reducing survival rates. While conventional screening methods such as chest X-rays and CT scans can detect certain abnormalities, they often lack the sensitivity to identify lung cancer in its earliest stages. This makes the search for more precise early detection methods essential for improving patient outcomes.
With the rapid development of precision medicine and genomics, cancer treatment is moving toward a more personalized approach. Personalized cancer care plans are tailored to each patient based on their genetic background, cancer type, immune status, and other physiological factors. RGCC (Research Genetic Cancer Centre) uses advanced genetic testing technologies to help cancer patients create more accurate care plans based on their individual genetic characteristics, enhancing treatment outcomes and minimizing side effects.
Cancer development is often the result of interactions between genetic and environmental factors. Understanding the genetic background of cancer is crucial for assessing individual risk, developing preventive strategies, and conducting early screenings.